Prevalence of Lung Cancer Screening in the US, 2022

Henderson, Louise M.; Su, I-Hsuan; Rivera, M. Patricia; Pak, Joyce; Chen, Xiaomeng; Reuland, Daniel S.; Lund, Jennifer L.

doi:10.1001/jamanetworkopen.2024.3190

JAMA Netw Open

2024

DOI: 10.1001/jamanetworkopen.2024.3190

|View full text |Cite

Prevalence of Lung Cancer Screening in the US, 2022

Louise M. Henderson,

I-Hsuan Su,

M. Patricia Rivera

et al.

Abstract: This cross-sectional study compares lung cancer screening prevalence in 2022 among individuals eligible by 2021 vs 2013 criteria by sociodemographics and state.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article5

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 10 publications

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Lung Cancer Screening Communication in the US, 2022

Sonawane,

Garg,

Toll

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

Lung Cancer Screening Communication in the US, 2022

Sonawane,

Garg,

Toll

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

show abstract

The American Cancer Society National Lung Cancer Roundtable strategic plan: Provider engagement and outreach

Lewis,

Klein,

Eberth

et al. 2024

Cancer

View full text Add to dashboard Cite

The American Cancer Society National Lung Cancer Roundtable strategic plan for provider engagement and outreach addresses barriers to the uptake of lung cancer screening, including lack of provider awareness and guideline knowledge about screening, concerns about potential harms from false‐positive examinations, lack of time to implement workflows within busy primary care practices, insufficient infrastructure and administrative support to manage a screening program and patient follow‐up, and implicit bias based on sex, race/ethnicity, social class, and smoking status. Strategies to facilitate screening include educational programming, clinical reminder systems within the electronic medical record, decision support aids, and tools to track nodules that can be implemented across a diversity of practices and health care organizational structures.Plain language summaryThe American Cancer Society National Lung Cancer Roundtable strategic plan to reduce deaths from lung cancer includes strategies designed to support health care professionals, to better understand lung cancer screening, and to support adults who are eligible for lung cancer screening by providing counseling, referral, and follow‐up.

show abstract

The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high‐quality lung cancer screening

Fathi,

Barry,

Greenberg

et al. 2024

Cancer

View full text Add to dashboard Cite

More than a decade has passed since researchers in the Early Lung Cancer Action Project and the National Lung Screening Trial demonstrated the ability to save lives of high‐risk individuals from lung cancer through regular screening by low dose computed tomography scan. The emergence of the most recent findings in the Dutch–Belgian lung‐cancer screening trial (Nederlands–Leuvens Longkanker Screenings Onderzoek [NELSON]) further strengthens and expands on this evidence. These studies demonstrate the benefit of integrating lung cancer screening into clinical practice, yet lung cancer continues to lead cancer mortality rates in the United States. Fewer than 20% of screen eligible individuals are enrolled in lung cancer screening, leaving millions of qualified individuals without the standard of care and benefit they deserve. This article, part of the American Cancer Society National Lung Cancer Roundtable (ACS NLCRT) strategic plan, examines the impediments to successful adoption, dissemination, and implementation of lung cancer screening. Proposed solutions identified by the ACS NLCRT Implementation Strategies Task Group and work currently underway to address these challenges to improve uptake of lung cancer screening are discussed.Plain language summaryThe evidence supporting the benefit of lung cancer screening in adults who previously or currently smoke has led to widespread endorsement and coverage by health plans. Lung cancer screening programs should be designed to promote high uptake rates of screening among eligible adults, and to deliver high‐quality screening and follow‐up care.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Prevalence of Lung Cancer Screening in the US, 2022

Abstract: This cross-sectional study compares lung cancer screening prevalence in 2022 among individuals eligible by 2021 vs 2013 criteria by sociodemographics and state.

Cited by 10 publications

References 8 publications

Lung Cancer Screening Communication in the US, 2022

Lung Cancer Screening Communication in the US, 2022

The American Cancer Society National Lung Cancer Roundtable strategic plan: Provider engagement and outreach

The American Cancer Society National Lung Cancer Roundtable strategic plan: Implementation of high‐quality lung cancer screening

Contact Info

Product

Resources

About